Form 4: Crinetics Pharmaceuticals Director Camille L. Bedrosian Reports Acquisition of Stock and Options

Director Camille L. Bedrosian reports acquisition of 3,400 shares of common stock and 12,500 stock options in Crinetics Pharmaceuticals.

Summary

• On June 7, 2024, Camille L. Bedrosian, a director of Crinetics Pharmaceuticals, reported acquiring 3,400 shares of common stock.
• These shares were received as restricted stock units.
• Bedrosian also acquired options to purchase 12,500 shares of common stock at an exercise price of $44.71.
• The restricted stock units vest on the earlier of the first anniversary of the grant date or the next annual meeting, contingent on continued service on the board.
• The stock options also vest on the earlier of the first anniversary of the grant date or the next annual meeting, contingent on continued service on the board, and expire on June 7, 2034.
• Following these transactions, Bedrosian directly owns 9,400 shares of Crinetics Pharmaceuticals common stock and options for 12,500 shares.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as a director is increasing their stake in the company, which is generally seen as a good sign. However, it's a routine transaction and doesn't necessarily indicate a major shift in the company's prospects.

Positives

• The acquisition of stock and options by a director signals confidence in the company's future prospects.
• The vesting conditions tied to continued service on the board align the director's interests with those of the shareholders.

Future Outlook

The vesting of the restricted stock units and stock options is contingent on the director's continued service on the board, suggesting a commitment to the company's future.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders. These filings are closely monitored by investors to gauge sentiment and potential future actions.

Stakeholder Impact

• The increased ownership by a director could positively influence shareholder confidence.

Key Dates